Current compound coverage of the kinome.
暂无分享,去创建一个
[1] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[2] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[3] Mark Johnson,et al. Using Molecular Equivalence Numbers To Visually Explore Structural Features that Distinguish Chemical Libraries , 2002, J. Chem. Inf. Comput. Sci..
[4] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[5] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[6] J. Mestan,et al. Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.
[7] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.
[8] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[9] A. Cheng,et al. Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index. , 2010, Journal of medicinal chemistry.
[10] R. Ward,et al. Kinase Drug Discovery , 2011 .
[11] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.
[12] K. Nguyen,et al. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. , 2012, Journal of medicinal chemistry.
[13] Jürgen Bajorath,et al. Extending the Activity Cliff Concept: Structural Categorization of Activity Cliffs and Systematic Identification of Different Types of Cliffs in the ChEMBL Database , 2012, J. Chem. Inf. Model..
[14] Jürgen Bajorath,et al. Growth of Ligand-Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity , 2012, J. Chem. Inf. Model..
[15] Jürgen Bajorath,et al. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..
[16] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[17] Jürgen Bajorath,et al. High-resolution view of compound promiscuity , 2013, F1000Research.
[18] Alexander Levitzki,et al. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. , 2013, Annual review of pharmacology and toxicology.
[19] Eddine Saiah,et al. Approaches to discover non-ATP site kinase inhibitors , 2013 .
[20] Jürgen Bajorath,et al. New frontiers in kinases: second generation inhibitors. , 2014, Journal of medicinal chemistry.
[21] I. D. de Esch,et al. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. , 2014, Journal of medicinal chemistry.
[22] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[23] S. Knapp,et al. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.
[24] Jürgen Bajorath,et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. , 2014, Journal of medicinal chemistry.